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While patients with chronic hepatitis C virus (HCV) infection are
treated in order to prevent liver-related morbidity and mortality,
we rely on sustained virological response (SVR) as a virological
biomarker to evaluate treatment efﬁcacy in both clinical practice
as well as in drug development. However, conclusive evidence for
the clinical beneﬁt of antiviral therapy or validity of SVR as sur-
rogate marker, as derived from trials randomizing patients to a
treatment or control arm, is lacking. In fact, the Hepatitis C Anti-
viral Long-term Treatment Against Cirrhosis (HALT-C) trial
recently showed an increased mortality rate among interferon-
treated patients compared to untreated controls. Consequently,
the recommendation to treat patients with chronic HCV infection
was challenged.
Here, we argue that the possible harmful effect of long-term
low-dose pegylated interferon mono therapy, as was observed
in the HALT-C trial cohort, cannot be extrapolated to potentially
curative short-term treatment regimens. Furthermore, we dis-
cuss SVR as a surrogate biomarker, based on numerous studies
which indicated an association between SVR and improvements
in health-related quality of life, hepatic inﬂammation and ﬁbro-
sis, and portal pressure as well as a reduced risk for hepatocellu-
lar carcinoma (HCC), liver failure and mortality.
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For the treatment of HCV infection we currently rely on inter-
feron-based antiviral regimens. These therapies are very effective
to prevent chroniﬁcation of the acute infection, and also have
good potential to eradicate HCV in those chronically infected
[1–4]. Sustained virological response (SVR) is deﬁned as absence
of viremia 24 weeks after cessation of antiviral therapy, which
showed long-term durability [5]. Consequently, antiviral therapy
is considered successful and patients are usually considered
‘cured’ upon achievement of SVR. Although SVR may be the most
widely used endpoint to evaluate antiviral treatment efﬁcacy, it
remains an indirect outcome measure. Indeed, the main reason
to treat patients with chronic HCV infection is to improve their
prognosis, by preventing cirrhosis-related morbidity and mortal-
ity. Are we convinced that the currently available treatment reg-
imens achieve this goal so that we are right to recommend
antiviral therapy to our patients?Findings of a recent Cochrane meta-analysis
Recently, this discussion ﬂared up due to the Cochrane review of
Dr. Koretz and colleagues which aimed to assess the efﬁcacy of
interferon-based re-treatment on solid clinical endpoints [6].
Their study included only randomized controlled trials (RCT), in
which patients with chronic HCV infection and non-response or
relapse to a prior interferon-based treatment course were ran-
domized to interferon re-treatment or no treatment. Extensive
literature searches resulted in seven eligible trials for meta-anal-
yses. For each endpoint of interest a subset of these trials was
used, depending on the described endpoints in the original study
reports. Only three trials reported on clinical outcomes, with all-
cause mortality as most deﬁnite endpoint [7–10]. These three
studies solely included patients with signiﬁcant hepatic ﬁbrosis
or cirrhosis, so that the meta-analyses on clinical outcomes
focused on a difﬁcult-to-treat subgroup of patients with
advanced liver disease and prior treatment failure. Combining
the results of these trials indicated a higher mortality rate among
interferon re-treated patients as compared to patients who did14 vol. 60 j 191–196
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not receive further antiviral therapy, although this difference was
not statistically signiﬁcant (Odds Ratio [OR] 1.30, 95% Conﬁdence
Interval [CI] 0.95–1.79). However, in a sensitivity analysis includ-
ing only the two largest trials with a low risk of bias, the disad-
vantage for patients who received interferon did reach
statistical signiﬁcance (OR 1.41, 95% CI 1.02–1.95). With respect
to the other clinical endpoints, the occurrence of liver-related
mortality, encephalopathy, ascites, spontaneous bacterial perito-
nitis, and hepatocellular carcinoma (HCC) was not found to differ
signiﬁcantly between re-treated patients and controls. An excep-
tion was variceal bleeding, which occurred signiﬁcantly less often
among the patients who were randomized to interferon-based
therapy (OR 0.26, 95% CI 0.09–0.71).
A secondary aim was to assess the validity of SVR as a surro-
gate endpoint of antiviral therapy. Although four studies reported
on this virological efﬁcacy measure, only two trials included
patients that actually attained SVR [8,10]. However, because of
the difﬁcult-to-treat patient population and the assessment of
suboptimal treatment regimens for HCV eradication, the number
of patients with SVR was very low. Nevertheless, and as expected,
SVR occurred more often among the patients treated with inter-
feron (OR 14.73, 95% CI 2.78–77.97). The meta-analyses thus
found a discrepancy between the effect of interferon therapy on
the surrogate outcome measure SVR and the clinical outcome
measure all-cause mortality, as both occurred more frequently
among actively treated patients.
The harmful effect of interferon-based therapy on survival,
which was found within clinical scenario of the included trials,
led to the conclusion that (pegylated) interferon is not an effec-
tive treatment option for patients with chronic HCV infection
who failed a previous antiviral treatment course. Since this
negative effect of interferon-based therapy was not captured by
suppression of HCV RNA, SVR failed the criteria to be considered
as a valid surrogate endpoint [11–14]. Based on these ﬁndings,
the authors subsequently stated that their results caution physi-
cians to stop advocating antiviral interventions of any kind.
Extrapolating their recommendation to anti-HCV therapy in gen-
eral was thus not discouraged by the fact that their meta-analy-
ses regarding all-cause mortality and SVR were almost
exclusively based on the Hepatitis C Antiviral Long-term Treat-
ment Against Cirrhosis (HALT-C) trial. However, this important
limitation warrants more careful interpretation of the results of
this review in order to prevent unbalanced statements with
potentially major consequences for the HCV-infected population.HALT-C trial
In brief, the HALT-C trial included 1050 patients with chronic
HCV infection and advanced hepatic ﬁbrosis, who were random-
ized to receive 3.5 years of 90 lg pegylated interferon alfa-2a
weekly or no treatment. Interferon maintenance therapy was
not found to slow down clinical and/or histological liver disease
progression [8]. In fact, a post hoc analysis after prolonging the
follow-up in this cohort indicated a poorer survival among
patients in the interferon maintenance arm, as the cumulative
7-year mortality rate was 20% in treated and 15% in control
patients (p = 0.049) [9]. This impaired overall survival was pre-
dominantly caused by deaths of non-liver-related origin among
patients with advanced hepatic ﬁbrosis (but not yet cirrhosis).192 Journal of Hepatology 201Based on this study, there is reasonable consensus that interferon
maintenance therapy has no regular place in the treatment of
chronic HCV infection. The ﬁndings of the recent Cochrane
meta-analysis further underline this general perception.
There are, however, several reasons not to withhold short-
term interferon-based therapy with the potential to eradicate
the chronic HCV infection based on the HALT-C trial results. First,
the patients in the control arm of the HALT-C trial were not treat-
ment naive. All included patients showed an insufﬁcient virolog-
ical response to a full–dose pegylated interferon and ribavirin
treatment course just prior to randomization. The survival among
patients who received interferon maintenance therapy for
3.5 years was thus signiﬁcantly reduced compared to that of
patients who received short-term interferon-based treatment,
indicating that the possible harmful effects of long-term pegylat-
ed interferon mono therapy cannot be projected onto standard
24–48 week regimens. Second, the increase in mortality only
began to arise after 3 years of pegylated interferon therapy, sug-
gesting that the possible off-target treatment effects require
long-term continuous interferon stimulation. Third, patients in
the control arm of the HALT-C more frequently underwent liver
transplantation, which can substantially prolong the survival.
Consequently, the survival also becomes dependent on non-
patient-related factors such as the availability of donor livers.
In fact, allocation of donor liver grafts based on the Model for
End-stage Liver Disease (MELD score) favors those patients with
poorest prognosis [15–17]. In the HALT-C trial, the 7-year cumu-
lative rate of all-cause mortality or liver transplantation as a
combined endpoint was similar among the patients who received
maintenance therapy (25%) vs. those who did not (24%, p = 0.45)
[9]. Last, as mentioned in the Cochrane review, the excess mortal-
ity in a subgroup of the treated patients in the HALT-C study
could be a chance ﬁnding. A signiﬁcant increase in mortality
due to interferon-based therapy was neither conﬁrmed in
another large RCT evaluating 5 years of maintenance therapy
(Evaluation of PegIntron in Control of Hepatitis C trial), nor in
smaller RCTs with shorter durations of interferon treatment
[7,10,18–24].
Furthermore, it can be questioned whether it is legitimate to
assess the validity of SVR as a surrogate marker with a trial that
did not aim to induce SVR and in fact assessed an interferon reg-
imen almost unable to result in this virological endpoint. Indeed,
the power was limited, as less than 4% of the treatment-experi-
enced patients with advanced hepatic ﬁbrosis attained SVR with
the low-dose pegylated interferon maintenance regimen. Surely,
these few patients with SVR could not signiﬁcantly affect the
clinical outcome of the entire treated study arm, whether or
not a harmful effect would have been present.SVR as surrogate endpoint
Currently, many clinical development trials aim to increase the
SVR rate of anti-HCV therapy. In support, there are numerous
arguments to consider SVR as a relevant endpoint. Treatment-
induced viral clearance is important to prevent transmission of
HCV and, even with the risk for re-infection among injecting drug
users, antiviral therapy will decrease the prevalence of chronic
HCV infection and the incidence of its sequelae [25,26]. Achieving
SVR before liver transplantation in patients with advanced4 vol. 60 j 191–196
JOURNAL OF HEPATOLOGY
cirrhosis showed to eliminate the risk for post-transplant HCV
recurrence, which is known to limit graft and overall survival
[27–29].
The majority of patients with chronic HCV infection are fortu-
nate not to develop cirrhosis and the need for liver transplanta-
tion [30]. Although clinical outcome is often focused on solid
cirrhosis-related endpoints such as hepatocellular carcinoma
and mortality, it should be noted that the health-related quality
of life is also impaired among patients with chronic HCV infection
in absence of end stage liver disease [31]. Indeed, extrahepatic
symptoms including fatigue, headaches, nausea, musculoskeletal
and abdominal pain, and neuropsychiatric symptoms like depres-
sion and irritability can accompany the chronic infection [32].
Multiple studies indicated that the health-related quality of life,
although further diminished for the duration of interferon-based
treatment, improved compared to baseline in patients who
attained SVR [31,33–37]. As the total burden of chronic HCV
infection extends beyond the liver, the impact of SVR on
patient-reported outcome measures covering physical, social as
well as mental health should be appreciated.
Still, the predominant consequences of infection with HCV
should be sought in the liver, where continuous inﬂammation
can lead to ﬁbrosis. Relevant are thus the many histological stud-
ies which showed regression of hepatic inﬂammation and ﬁbro-
sis, as assessed by semi-quantitative grading and staging scores
(Ishak and METAVIR), after interferon-induced eradication of
HCV as the causative agent [38–45]. These histological improve-
ments were frequently observed among patients who had already
developed cirrhosis as well. In addition, the quantitatively mea-
sured total liver collagen content was also described to reduce
upon achievement of SVR [38,46,47]. In fact, among patients with
cirrhosis who did not show an improved METAVIR score in their
post-SVR liver biopsy, the total amount of ﬁbrosis was still signif-
icantly reduced [38]. Two prior Cochrane meta-analyses indi-
cated that, compared to no treatment, interferon signiﬁcantly
improved liver histology, and that regression of hepatic ﬁbrosis
was more often achieved with interferon and ribavirin combina-
tion therapy compared to interferon therapy alone [48,49]. An
important study by Mallet et al. linked the histological improve-
ment following antiviral therapy to a favorable clinical outcome,
as the ‘regression of cirrhosis’ was associated with reduced occur-
rence of cirrhosis-related morbidity and prolonged overall sur-
vival [40].
Improved histology could explain the reduction in portal pres-
sure among patients with SVR, as measured by the hepatic
venous pressure gradient (HVPG) [50–52]. Importantly, the HVPG
is one of the best validated surrogate markers within the ﬁeld of
hepatology, as higher HVPG levels are associated with worse clin-
ical outcome and RCTs have indicated that interventions to
reduce the portal pressure resulted in both decreased HVPG
levels as well as improved clinical outcome [12,53–55]. Indeed,
cirrhotic patients with chronic HCV infection who attained SVR
did not develop esophageal varices or variceal bleeding, the most
direct clinical complication of portal hypertension which is asso-
ciated with substantial mortality [50,56].
Several Western cohort studies assessed the relation between
SVR and the occurrence of solid clinical endpoints such as liver
failure, hepatocellular carcinoma, liver transplantation and death
[56–61]. Our group was one of the ﬁrst to show that patients with
chronic HCV infection and advanced hepatic ﬁbrosis had aJournal of Hepatology 201reduced risk for liver failure as well as liver-related mortality
already shortly after SVR [62]. Studies with longer follow-up con-
ﬁrmed that these events remained rare among successfully trea-
ted patients, and also indicated a strong association between SVR
and reduced occurrence of HCC (hazard ratios [HR] varying from
0.19 to 0.38) [56–60]. A partially prospective study with up to
7.5 years of follow-up found that all-cause mortality or liver
transplantation, as a combined endpoint, occurred signiﬁcantly
less often among patients with SVR compared to those with viro-
logical non-response (HR 0.17, 95% CI 0.06–0.46, p <0.001). In a
multicenter study from Spain, which included 1599 patients with
chronic HCV and human immunodeﬁciency virus co-infection
who were followed for a median of approximately 5 years, SVR
was independently associated with a reduced risk for non-liver-
related, non-AIDS-related deaths (HR 0.35, 95% CI 0.13–0.93,
p = 0.036) [63]. Population-based studies indicated a favorable
overall survival among HCV-exposed patients without detectable
HCV RNA. A study, expected to include over 90% of all Danish
patients tested for HCV RNA, found a signiﬁcantly lower 5-year
survival among patients with chronic HCV infection compared
to those who cleared HCV RNA (86% vs. 92%, respectively) [61].
Recent data from the Risk Evaluation of Viral Load Elevation
and Associated Liver Disease/Cancer (R.E.V.E.A.L.)-HCV study, a
prospective natural history study from Taiwan including 19,636
HBsAg-seronegative patients, indicated that the cumulative 18-
year all-cause mortality rate was similar among anti-HCV sero-
positive patients with undetectable HCV RNA (12.4%) and anti-
HCV seronegative patients (12.8%) [64]. In contrast, the mortality
rate was substantially higher among anti-HCV seropositive
patients with detectable HCV RNA (30.1%; p <0.001). Recently,
important data have emerged regarding the association between
SVR and reduced all-cause mortality as well. Multivariate analy-
ses, stratiﬁed for HCV genotype, indicated SVR was indepen-
dently associated with reduced risk for death of any cause (HR
0.51–0.70, p <0.01 for HCV genotypes 1, 2, and 3) among almost
17,000 American veterans with chronic HCV infection and vary-
ing stages of liver disease [65]. An update of our cohort, including
530 patients with HCV-induced advanced hepatic ﬁbrosis or cir-
rhosis, resulted in a median follow-up duration of 8.4 years, and
showed a 10-year cumulative all-cause mortality rate of 9%
among patients with SVR compared to 26% among patients with-
out SVR (p <0.001) [56]. Multivariate analyses indicated that SVR
was the most important factor that was independently associated
with improved survival, as patients with SVR had an approxi-
mately four-fold lower mortality risk compared to those without
SVR (HR 0.26, 95% CI 0.14–0.49, p <0.001). Together these large
follow-up studies provide the most important data to endorse
SVR as a relevant endpoint, as all showed similar and conclusive
ﬁndings with strong adjusted hazard ratios for the association
between SVR and improved clinical outcome.Randomized controlled trials reporting on clinical outcome
It should, however, be recognized that cohort studies suggesting
a clinical beneﬁt of SVR share a similar limitation. Despite exten-
sive multivariate analyses, the association between SVR and
improved clinical outcome remains potentially inﬂuenced by
unmeasured confounding factors [66]. In other words, observa-
tional studies cannot rule out the possibility that patients who4 vol. 60 j 191–196 193
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have attained SVR are merely a selection of patients who would
have a favorable natural history if left untreated as well. Indeed,
several host and viral factors were related to a favorable long-
term clinical outcome as well as to an adequate virological
response to interferon-based therapy [56,58,59,67,68]. Thus, the
frequently reported association between SVR and improved clin-
ical outcome from cohort studies neither validates SVR as a sur-
rogate endpoint nor conﬁrms that antiviral therapy has clinical
beneﬁts. This requires RCTs to indicate that interferon therapy
positively affects SVR as well as clinical outcome [11–14]. As dis-
cussed, this was not the case in the latest Cochrane meta-analysis
[6].
Since RCTs on solid clinical endpoints usually require long and
costly prospective follow-up, especially in a slowly progressive
disease as chronic hepatitis C, it is not surprising that only few
have been performed. The trials that have been performed all
exclusively included patients with advanced liver disease, proba-
bly because these patients are at highest risk for clinical events.
Due to the restriction to interferon re-treatment, not all RCTs
reporting on clinical outcome events were included in the recent
Cochrane review. Unfortunately, however, most of the additional
trials are limited by a low number of included patients and the
use of interferon-based regimens with relatively low antiviral
efﬁcacy [10,18–24]. Especially among patients with cirrhosis,
SVR rates of the early interferon-based antiviral regimens have
been poor [69]. Although several trials did report a clinical bene-
ﬁt of interferon-based antiviral therapy, the results varied and
not all positive trials were without controversy [10,18,22,23].
Therefore, deﬁnite evidence for the clinical efﬁcacy of interferon
therapy was never established and SVR was never formally vali-
dated. The use of SVR as surrogate outcome measure thus
remains with some uncertainty. Nevertheless, another recent
Cochrane meta-analysis did indicate that the combination of
interferon and ribavirin signiﬁcantly reduced morbidity plus
mortality, as a composite clinical endpoint, compared to inter-
feron mono therapy [49]. This ﬁnding is in line with the increase
in SVR rate due to the addition of ribavirin to interferon therapy
[70,71].
Presently, new treatment regimens and the introduction of
protease inhibitors have substantially increased the antiviral efﬁ-
cacy of interferon-based therapy. Also for patients with cirrhosis,
pegylated interferon and ribavirin combination therapy (with the
addition of a protease inhibitor for those with HCV genotype 1) is
likely to increase SVR rates to above 50% [2–4,72–76]. None of the
RCTs on clinical efﬁcacy have assessed a full-dose pegylated
interferon and ribavirin treatment course, however, while this
has been the standard of care over the last decade. Future inter-
feron-free regimens are even expected to further enhance antivi-
ral efﬁcacy, while simultaneously reducing treatment duration
and improving side-effect proﬁles [77,78]. Thus, assuming the
biologically plausible causal relation between HCV eradication
and improved clinical outcome, RCTs with current antiviral regi-
mens would have higher power to show a clinical beneﬁt of anti-
viral therapy as well as to validate SVR as surrogate endpoint.
However, the accumulated data suggesting patients beneﬁt from
SVR impedes justiﬁcation of trials in which patients are denied a
chance to eradicate their chronic HCV infection. Ethical concerns
thus prevent us from performing the trials which could bring
conclusive evidence regarding the clinical efﬁcacy of antiviral
therapy. Such trials should thus not be awaited for the decision
to initiate antiviral therapy in the individual patient.194 Journal of Hepatology 201Key Points• The recommendation to treat hepatitis C was recently
challenged because patients receiving interferon 
maintenance therapy within the HALT-C trial had an
increased mortality rate as compared to controls, 
despite attaining SVR more frequently
• The possible increase in mortality due to long-term
interferon maintenance therapy cannot be extrapolated
to the commonly applied short-term interferon-based
regimens with the potential to eradicate the HCV 
infection
• Achievement of SVR has been repeatedly associated
with regression of hepatic fibrosis, reduction of portal
pressure, a lower risk for liver failure and hepatocellular
carcinoma, as well as with an improved overall survival
• As viral eradication is likely to improve their prognosis,
physicians should continue to treat their patients with
chronic HCV infectionConclusion
To conclude, we are aware that deﬁnite proof for the surrogacy of
SVR and clinical beneﬁt of interferon-based antiviral therapy is
lacking. Nevertheless, SVR has been repeatedly associated with
improvements in health-related quality of life, hepatic inﬂamma-
tion and ﬁbrosis, and portal pressure as well as with a reduced
occurrence of solid clinical endpoints such as hepatocellular car-
cinoma, liver failure and death. Collectively, this strongly argues
that SVR is a patient-relevant endpoint and reasonably likely to
predict clinical beneﬁt [13]. Furthermore, there is no clear evi-
dence to suggest a long-term harmful effect of 24–48 weeks of
interferon-based therapy, by which we usually attempt to
achieve this virological outcome measure in our patients. With
future triple therapy, a treatment duration of 12 weeks might
even be sufﬁcient [79]. The increased mortality rate in a subgroup
of patients who received long-term interferon maintenance ther-
apy is not representative for short-term antiviral therapy with
the potential to result in SVR. Nevertheless, we do acknowledge
that interferon-based therapy is accompanied by substantial
side-effects, which was also highlighted again by the recent
meta-analysis [6]. Thus, careful patient selection remains a
necessity at this time, and better tolerated interferon-free treat-
ment regimens with combinations of direct-acting antiviral
agents are urgently required. We oppose, however, that the
results of the recent Cochrane meta-analysis, or more speciﬁcally
the HALT-C study, should discourage physicians from treating
their patients with chronic HCV infection in general.Conﬂict of interest
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